Our top pick for
Building a portfolio
Eyenovia, Inc is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Eyenovia employs 27 staff and has a market cap (total outstanding shares value) of USD$141.6 million.
|Latest market close||USD$3.94|
|52-week range||USD$1.11 - USD$6.12|
|50-day moving average||USD$3.9535|
|200-day moving average||USD$3.5321|
|Wall St. target price||USD$12|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.968|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-39.94%|
|1 month (2020-12-23)||-31.72%|
|3 months (2020-10-22)||12.89%|
|6 months (2020-07-22)||8.24%|
|1 year (2020-01-22)||-13.97%|
|2 years (2019-01-22)||35.40%|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-58.33%|
|Return on equity TTM||-118.7%|
|Market capitalisation||USD$141.6 million|
TTM: trailing 12 months
There are currently 50,026 Eyenovia shares held short by investors – that's known as Eyenovia's "short interest". This figure is 38.5% down from 81,366 last month.
There are a few different ways that this level of interest in shorting Eyenovia shares can be evaluated.
Eyenovia's "short interest ratio" (SIR) is the quantity of Eyenovia shares currently shorted divided by the average quantity of Eyenovia shares traded daily (recently around 172503.44827586). Eyenovia's SIR currently stands at 0.29. In other words for every 100,000 Eyenovia shares traded daily on the market, roughly 290 shares are currently held short.
However Eyenovia's short interest can also be evaluated against the total number of Eyenovia shares, or, against the total number of tradable Eyenovia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eyenovia's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Eyenovia shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Eyenovia shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eyenovia.
Find out more about how you can short Eyenovia stock.
We're not expecting Eyenovia to pay a dividend over the next 12 months.
Over the last 12 months, Eyenovia's shares have ranged in value from as little as $1.11 up to $6.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 2.087. This would suggest that Eyenovia's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.